Rep. Kevin Hern Sells Exact Sciences Corporation (NASDAQ:EXAS) Stock

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Exact Sciences Corporation (NASDAQ:EXAS). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in Exact Sciences stock on March 24th. The trade occurred in the Representative’s “GABRIELLE ASHTYN HERN TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 3/17/2026.

Exact Sciences Price Performance

NASDAQ EXAS opened at $104.91 on Tuesday. The business has a 50 day simple moving average of $103.62 and a 200 day simple moving average of $90.07. Exact Sciences Corporation has a 52-week low of $38.81 and a 52-week high of $104.98. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43. The stock has a market cap of $20.03 billion, a price-to-earnings ratio of -95.37, a PEG ratio of 2.02 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). The business had revenue of $878.38 million for the quarter, compared to the consensus estimate of $860.59 million. Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.Exact Sciences’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.06) earnings per share. Analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exact Sciences

Hedge funds have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC acquired a new stake in Exact Sciences during the 4th quarter valued at $26,000. Torren Management LLC acquired a new stake in Exact Sciences during the 4th quarter valued at $27,000. Hantz Financial Services Inc. lifted its holdings in Exact Sciences by 100.5% during the 4th quarter. Hantz Financial Services Inc. now owns 421 shares of the medical research company’s stock valued at $43,000 after purchasing an additional 211 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Exact Sciences during the 4th quarter valued at $44,000. Finally, Westside Investment Management Inc. lifted its holdings in Exact Sciences by 100.0% during the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 271 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Zacks Research cut shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research note on Thursday, January 22nd. Mizuho reaffirmed a “neutral” rating and set a $105.00 price target (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Evercore set a $105.00 price target on shares of Exact Sciences and gave the stock an “in-line” rating in a research note on Monday, January 5th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a research note on Tuesday, March 24th. Twenty-one research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $92.13.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.